Adipose Tissue Secretome Biomarkers in Metabolic Health

Abstract

Adipose tissue functions as an active endocrine organ, releasing a complex secretome of bioactive molecules that play pivotal roles in metabolic health. Recent research has identified an array of adipokines, cytokines, and extracellular vesicles secreted by adipocytes, which serve as biomarkers for metabolic diseases such as obesity, insulin resistance, and type 2 diabetes mellitus. This review synthesizes current evidence on the clinical utility of adipose tissue secretome biomarkers, elucidates their mechanistic underpinnings, and discusses their diagnostic and therapeutic relevance. Special attention is given to emerging therapies targeting the adipose secretome and guideline-based recommendations for clinical practice.

Introduction

Adipose tissue, traditionally viewed as a passive fat storage depot, has been redefined as a dynamic endocrine organ with vast implications for metabolic homeostasis. The adipose tissue secretome encompasses a diverse group of proteins, lipids, nucleic acids, and extracellular vesicles that exert autocrine, paracrine, and endocrine effects. Dysfunction in adipose secretory function is closely linked to the pathogenesis of metabolic syndrome, insulin resistance, and cardiovascular disease. Recent advances in biomarker discovery have highlighted the clinical potential of secretome profiling to predict, diagnose, and monitor metabolic health.

Epidemiology / Disease Burden

Metabolic disorders, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD), represent a global health crisis, affecting hundreds of millions worldwide. As the prevalence of obesity continues to rise, so does the burden of associated comorbidities. Adipose tissue dysfunction is a central feature of these diseases, underpinning the need for reliable biomarkers to stratify risk, guide interventions, and monitor therapeutic response.

Pathophysiology

The secretome of adipose tissue comprises adipokines such as adiponectin, leptin, resistin, visfatin, and pro-inflammatory cytokines including TNF-α and IL-6. In healthy individuals, the adipose secretome maintains insulin sensitivity, modulates appetite, and regulates lipid metabolism. In obesity, hypertrophic adipocytes secrete increased levels of inflammatory cytokines while reducing beneficial adipokines, leading to chronic low-grade inflammation, insulin resistance, and endothelial dysfunction. Extracellular vesicles released from dysfunctional adipose tissue further propagate metabolic derangements via miRNA and protein cargo delivery to distant organs.

Risk Factors

Key risk factors for adipose tissue secretome dysregulation include excessive caloric intake, sedentary lifestyle, genetic predisposition, and aging. Central adiposity, particularly visceral fat accumulation, is strongly associated with a pro-inflammatory secretome profile. Other modifiable risk factors include poor dietary patterns, chronic stress, and exposure to endocrine-disrupting chemicals. Non-modifiable factors such as ethnicity and family history also influence secretome composition and metabolic risk.

Clinical Features

Clinical manifestations of adipose tissue secretome dysregulation are often subtle and evolve over time. Early features include increased waist circumference, subclinical inflammation, and mild insulin resistance. As the secretome shifts towards a pro-inflammatory phenotype, patients may present with overt metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, and NAFLD. Long-term consequences include accelerated atherosclerosis, cardiovascular events, and increased mortality.

Diagnosis

Diagnosis of metabolic dysfunction secondary to adipose tissue secretome imbalance involves a combination of clinical assessment and laboratory investigations. Measurement of circulating adipokines such as adiponectin (typically reduced) and leptin (often elevated) provides insight into adipose tissue health. Emerging biomarkers, including omentin, chemerin, and specific exosomal miRNAs, are under investigation for their diagnostic utility. Comprehensive metabolic panels, inflammatory markers (CRP, IL-6), and imaging studies for fat distribution (MRI, DEXA) complement secretome profiling in clinical practice.

Treatment & Management

Management strategies aim to restore a healthy adipose tissue secretome through lifestyle modification, pharmacotherapy, and surgical interventions. Weight loss via caloric restriction and increased physical activity is the cornerstone of therapy, leading to improved adipokine profiles and reduced inflammation. Pharmacological agents such as thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors have demonstrated beneficial effects on adipose secretory function. Bariatric surgery induces profound changes in the secretome, correlating with improvements in metabolic parameters.

Recent Advances / Emerging Therapies

Recent advances in secretome research have identified novel biomarkers with potential for early detection and targeted therapy. Extracellular vesicles, particularly exosomes carrying anti-inflammatory miRNAs, are being explored as therapeutic agents and disease biomarkers. Monoclonal antibodies targeting pro-inflammatory adipokines, gene editing technologies, and small molecule modulators of adipose tissue inflammation represent promising avenues for intervention. High-throughput proteomics and single-cell secretome analysis are enhancing our understanding of adipose tissue heterogeneity and its clinical implications.

Guideline Recommendations

Current clinical guidelines emphasize the importance of lifestyle modification as the primary approach to improving adipose tissue function and metabolic health. The American Diabetes Association and European Association for the Study of Diabetes recommend routine assessment of adiposity and metabolic risk factors in at-risk populations. While secretome biomarkers are not yet standard in routine care, their inclusion in risk stratification algorithms is anticipated as evidence accrues. Multidisciplinary care involving endocrinologists, dietitians, and primary care providers is essential for effective management.

Conclusion

The adipose tissue secretome represents a critical nexus in the regulation of metabolic health, offering valuable insights into disease pathogenesis, risk stratification, and therapeutic targets. Continued research into secretome biomarkers holds promise for precision medicine approaches to metabolic disease. Integration of secretome profiling into clinical practice will enhance early detection, individualized treatment, and improved outcomes for patients with metabolic disorders.